Assoc Prof Philip Beale highlights the results of DESKTOP3, which were presented at ASCO 2020:
“This trial is the first trial to demonstrate a survival benefit in patients undergoing surgery for recurrent platinum-sensitive ovarian cancer. This trial is potentially practice-changing.
The trial demonstrates that the patients do need to fit the entry criteria which is a positive AGO score and 75% of the patients had a platinum-free interval of more than 12 months. The other major issue was the importance of achieving a complete resection. Those who underwent surgery and did not achieve a complete resection did worse than those who did not have surgery.”